Plasmin induces the formation of multicellular spheroids of breast cancer cells

Cancer Letters

Volumn 117, Issue 1, 1997, Pages 51-56

  Chun, Myung H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Monolayer; Plasmin; Spheroids; Urokinase

Indexed keywords

DOXORUBICIN; PACLITAXEL; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE; STREPTOKINASE; UROKINASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; MALE; MULTICELLULAR SPHEROID; NORMAL HUMAN; PRIORITY JOURNAL; SERUM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; DOXORUBICIN; HUMANS; ORGANOIDS; PACLITAXEL; PLASMIN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030765564     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00213-9     Document Type: Article

References (33)

1. J.R. Harris, M. Morrow, G. Bonadonna, Cancer of the breast, in: V. Devita Jr., S. Hellman, S. Rosenberg (Eds.), Cancer Principles and Practice of Oncology, J.B. Lippincott, Philadelphia, PA, 1993, 4th ed., pp. 1264-1331.
2. R.N.M. McSwann, K. Whaley (Eds.), Muir's Textbook of Pathology, Edward Arnold, London, 1993, 13th ed., pp. 13-22.
3. H.D. Soule, J. Vazquez, A. Long, M.A. Brennan, Human cell line from a pleural effusion derived from a breast carcinoma, J. Natl. Cancer Inst. 51 (1973) 1409-1416.
4. L.W. Engel, N.A. Young, T.S. Tralka, M.E. Lippman, S.J. O'Brien, M.J. Joyce, Establishment and characterization of three new continuous cell lines derived from human breast carcinomas, Cancer Res. 38 (1978) 3352-3358.
5. R.E. Durand, Flow cytometry studies of intracellular adriamycin in multicell spheroid in vitro, Cancer Res. 41 (1981) 3495-3498.
6. C. Erlichman, D. Vidgen, Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice, Cancer Res. 44 (1984) 5369-5375.
7. B. Glimelius, B. Norling, T. Nederman, J. Carllsson, Extracellular matrices in multicellular spheroids of human glioma origin: increased incorporation of proteoglycans and fibronectin as compared to monolayer cell cultures, AMPIS 96 (1988) 433-444.
8. A. Gorlach, P. Herter, H. Hentschel, P.J. Frosch, H. Acker, Effects of nIFN b and rIFN r on growth and morphology of two human melanoma cell lines: comparison between two-and three-dimensional culture, Int. J. Cancer 56 (1994) 249-261.
9. T. Nederman, Effects of vinblastin and 5-flurouracin on human glioma and thyroid cancer cell monolayers and spheroids, Cancer Res. 44 (1984) 254-258.
10. R.M. Sutherland, J.A. McCredie, W.R. Inch, Growth of multicell spheroids in tissue culture as a model of nodular carcinoma, J. Natl. Cancer Inst. 46 (1971) 113-120.
11. R.M. Sutherland, Cell and environmental interactions in tumor microregion: the multicell spheroid model, Science 240 (1988) 177-184.
12. S. Walenta, A. Bredel, U. Karbach, L. Kunz, W.Vollrath, eller-KlieserMu, Interrelationship among morphology, metabolism, and proliferation of tumor cells in monolayer and spheroid culture, Adv. Exp. Med. Biol. 248 (1989) 847-853.
13. G.W. West, R. Weichselbaum, J.B. Little, Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy, Cancer Res. 40 (1980) 3665-3668.
14. J.M. Yuhas, A.P. Li, A.O. Martinez, A.J. Ladman, A simplified method for production and growth of multicellular spheroids, Cancer Res. 37 (1977) 3639-3643.
15. S. Pollack, A. Micali, W.E. Enker, D.W. Kinne, A. Geller, H.F. Oettgen, M.K. Hoffmann, Endotoxin-induced in vitro release of interleukin-1 by cancer patients' monocytes: relation to stage of disease, Int. J. Cancer 15 (1983) 733-736.
16. T. Mosmann, Rapid colometric assay for cellular growth and survival: application to proliferation and cytotoxic assays, J. Immunol. Methods 65 (1983) 55-63.
17. F. Bachmann, The plasminogen-plasmin enzyme system in hemostasis and thrombosis, in: R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.), Basic Principles and Clinical Practice, J.B. Lippincott, Philadelphia, PA, 1994, 3rd ed., pp. 1592-1622.
18. F. Blasi, J.D. Vassali, K. Dano, Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors, J. Cell Biol. 104 (1987) 801-804.
19. D. Collen, H.R. Lijnen, P.A. Todd, K.L. Goa, Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent, Drugs 38 (1989) 346-388.
20. F. Fazioli, F. Blasi, Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci. 15 (1994) 25-29.
21. O. Saksela, D.B. Rifkin, Cell-associated plasminogen activation: regulation and physiological functions, Annu. Rev. Cell Biol. 4 (1988) 93-126.
22. E. Bianchi, R.L. Cohen, A.T. Thor, R.F. Todd III, I.F. Mizukami, D.A. Lawrence, B.M. Ljung, M.A. Shuman, H.S. Smith, The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue, Cancer Res. 54 (1994) 861-866.
23. S.S. Husain, V. Curewich, B. Lipinski, Purification and partial characterization of single-chain molecular weight-form of urokinase from human urine, Arch. Biochem. Biophys. 220 (1983) 31-38.
24. H. Sumi, K. Robbins, A functionally active heavy chain derived from human high molecular weight urokinase, J. Biol. Chem. 258 (1983) 8014-8019.
25. V. Ellis, C. Pyke, J. Eriksen, H. Solberg, K. Dano, The urokinase receptor involvement in cell surface proteolysis and cancer invasion, Ann. N. Y. Acad. Sci. 667 (1992) 13-31.
26. A. Roldan, M.V. Cubellis, M.T. Masucci, N. Beherendt, L.R. Lund, K. Dano, E. Appella, F. Blasi, Cloning and expression of the receptors for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent protease, EMBO J. 9 (1990) 467-474.
27. V. Ellis, M.F. Scully, V.V. Kakkar, Plasminogen activation initiated by single-chain urokinase in functional isolation. Potentiation by U937 monocytes, J. Biol. Chem. 264 (1989) 2185-2188.
28. M. Kohler, S. Sen, C. Miyashita, Half-life of single chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infraction, Thromb. Res. 62 (1991) 75-81.
29. N. Manchanda, B.S. Schwartz, Single chain urokinase: augmentation of enzymatic activity upon binding to monocytes, J. Biol. Chem. 266 (1991) 14580-14584.
30. R.J. Cote, P.P. Rosen, M.L. Lesser, L.J. Old, M.P. Osborne, Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases, J. Clin. Oncol. 9 (1991) 1749-1884.
31. Early Breast Cancer Trialists' Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy, Lancet 339 (1992) 1-15.
32. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. Lancet, 339 (1992) 71-86.
33. B.H. Munro, E. Batten, Statistical Methods for Health Care Research, J.B. Lippincott, Philadelphia, PA, 1993, pp. 99-105.